Insider trading

Period: 120 months Stock: ROIV Role: CEO × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

41 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

41 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

41 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

41 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
41 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
41 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

41 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
30 Sep 2026
Venker Eric President & Immunovant CEO
Sold on a plan
$7.32M 200,000 at 36.62
11.1%
Planned (10b5-1)
28 Aug 2026
Venker Eric President & Immunovant CEO
Sold on a plan 2×
$7.15M 200,000 at 35.77
11.1%
Planned (10b5-1)
27 Jul 2026
Venker Eric President & Immunovant CEO
Sold on a plan
$6.99M 200,000 at 34.95
11.0%
Planned (10b5-1)
24 Jun 2026
Venker Eric President & Immunovant CEO
Sold on a plan 2×
$6.63M 200,000 at 33.16
11.0%
Planned (10b5-1)
22 May 2026
Venker Eric President & Immunovant CEO
Sold on a plan
$6.05M 200,000 at 30.27
11.0%
Planned (10b5-1)
20 Apr 2026
Venker Eric President & Immunovant CEO
Sold on a plan
$5.92M 200,000 at 29.59
10.8%
Planned (10b5-1)
16 Apr 2026
Sold at will
$8.45M 289,774 at 29.16
1.7%
Not planned
17 Mar 2026
Venker Eric President & Immunovant CEO
Sold on a plan
$5.65M 200,000 at 28.24
10.8%
Planned (10b5-1)
13 Feb 2026
Venker Eric President & Immunovant CEO
Sold on a plan
$5.30M 200,000 at 26.49
10.8%
Planned (10b5-1)
12 Jan 2026
Venker Eric President & Immunovant CEO
Sold on a plan
$4.38M 200,000 at 21.92
10.8%
Planned (10b5-1)
24 Dec 2025
Venker Eric President & Immunovant CEO
Sold at will
$1.69M 75,000 at 22.53
4.3%
Not planned
23 Dec 2025
Venker Eric President & Immunovant CEO
Sold at will
$4.49M 200,000 at 22.45
11.0%
Not planned
15 Dec 2025
Sold at will 3×
$37.72M 1,740,000 at 21.68
9.1%
Not planned
9 Dec 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$4.17M 200,000 at 20.85
11.8%
Planned (10b5-1)
7 Nov 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$4.04M 200,000 at 20.22
11.7%
Planned (10b5-1)
17 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$2.02M 118,418 at 17.06
7.3%
Planned (10b5-1)
16 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$5.43M 318,282 at 17.05
17.5%
Planned (10b5-1)
15 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$7.02M 414,683 at 16.93
21.6%
Planned (10b5-1)
13 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$336.81K 20,727 at 16.25
1.4%
Planned (10b5-1)
9 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$1.71M 104,940 at 16.30
6.5%
Planned (10b5-1)
8 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$2.25M 138,602 at 16.20
8.4%
Planned (10b5-1)
7 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$5.74M 355,161 at 16.15
19.1%
Planned (10b5-1)
6 Oct 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$2.80M 171,396 at 16.34
10.2%
Planned (10b5-1)
23 Sep 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$9.06M 611,000 at 14.83
28.9%
Planned (10b5-1)
22 Sep 2025
Venker Eric President & Immunovant CEO
Sold on a plan 2×
$6.24M 416,182 at 14.99
16.4%
Planned (10b5-1)
19 Sep 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$10.22M 683,818 at 14.95
25.8%
Planned (10b5-1)
18 Sep 2025
Bought
$49.96K 3,315 at 15.07
0.0%
First buy on file
20 Aug 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$1.17M 100,000 at 11.72
5.7%
Planned (10b5-1)
21 Jul 2025
Venker Eric President & Immunovant CEO
Sold on a plan
$1.15M 100,000 at 11.52
6.4%
Planned (10b5-1)
23 Sep 2024
Sold on a plan
$23.38M 1,983,257 at 11.79
10.0%
Planned (10b5-1)
25 Oct 2022
Sold, plan not stated
$84.81K 19,276 at 4.40
1.6%
23 Sep 2022
Sold, plan not stated
$64.63K 21,053 at 3.07
1.7%
24 Aug 2022
Sold, plan not stated
$74.23K 20,009 at 3.71
1.6%
25 Jul 2022
Sold, plan not stated
$88.57K 20,455 at 4.33
1.6%
23 Jun 2022
Sold, plan not stated
$86.17K 19,855 at 4.34
1.6%
20 May 2022
Sold, plan not stated
$517.23K 139,791 at 3.70
10.0%
25 Apr 2022
Sold, plan not stated
$32.67K 8,509 at 3.84
0.6%
30 Mar 2022
Sold, plan not stated
$163.04K 33,686 at 4.84
2.3%
25 Mar 2022
Sold, plan not stated
$179.05K 35,386 at 5.06
2.3%
18 Mar 2022
Sold, plan not stated
$420.69K 82,006 at 5.13
5.2%
7 Mar 2022
Sold, plan not stated
$509.63K 92,324 at 5.52
5.5%
Showing 1–41 of 41.